 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C34H50O7 |
| Molecular Weight | 570.76 |
| CAS # | 110024-14-1 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Caspase-3 Caspase-9 |
| ln Vitro | In comparison to normal human cell lines, ganoderic acid Mk (0-100 μM, 24 h) displays greater cytotoxicity against human cancer cells [1]. HeLa cell growth is dose-dependently inhibited by ganoderic acid Mk (0–40 μM, 12-48 h) [1]. HeLa cells undergo apoptosis when exposed to gonadoderic acid Mk (0–40 μM, 24 h)[1]. Ganoderic acid Mk (0-40 μM, 24 h) causes a rise in caspase-3 and -9 activity, a reduction in MMP, and a burst of ROS [1]. |
| Cell Assay |
Cell Cytotoxicity Assay[1] Cell Types: Human normal cell lines (MCF-10A and HF) and cancer cell lines (HO- 8910PM, SW1990, 95-D and HeLa) Tested Concentrations: 0-100 μM Incubation Duration: 24 h Experimental Results: demonstrated stronger cytotoxicity to human cancer cells (IC50 values were ranged within 29.8-44.2 µM) than human normal cell lines (IC50 values to MCF-10A and HF were 84.5 µM and 78.4 µM, respectively). Cell Viability Assay[1] Cell Types: HeLa cells Tested Concentrations: 0, 5, 10, 20, 40 μM Incubation Duration: 12, 24, 48 h Experimental Results: demonstrated cytotoxicity on HeLa cells in a dose- and time-dependent manner. Apoptosis Analysis[1] Cell Types: HeLa cells Tested Concentrations: 0, 10, 20, 40 μM Incubation Duration: 24 h Experimental Results: Increased the rate of early and late apoptotic cells in a dose-dependent manner in HeLa cells. GA-Mk could induce HeLa cells apoptosis in parallel with the accumulation of ROS, the loss of MMP and the activation of activities of caspases. |
| References |
[1]. Anti-proliferation and induced mitochondria-mediated apoptosis of ganoderic acid Mk from Ganoderma lucidum mycelia in cervical cancer HeLa cells. Latin American Journal of Pharmacy, 2012, 31(1):43-50. [2]. Separation and determination of four ganoderic acids from dried fermentation mycelia powder of Ganoderma lucidum by capillary zone electrophoresis. J Pharm Biomed Anal. 2010 Dec 15;53(5):1224-30. |
Solubility Data
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7520 mL | 8.7602 mL | 17.5205 mL | |
| 5 mM | 0.3504 mL | 1.7520 mL | 3.5041 mL | |
| 10 mM | 0.1752 mL | 0.8760 mL | 1.7520 mL |